Real-World Analysis of the Enfortumab Vedotin-Ineligible criTeriA Assessment in Treatment-Naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma

被引：0
|
作者：
Miyake, Makito [1 ]
Nishimura, Nobutaka [1 ]
Oda, Yuki [1 ]
Shimizu, Takuto [1 ]
Iida, Kota [1 ]
Fujimoto, Kiyohide [1 ]
机构：
[1] Nara Med Univ, Dept Urol, Nara, Japan
来源：
INTERNATIONAL JOURNAL OF UROLOGY | 2025年
关键词：
chemotherapy; enfortumab vedotin; EVITA; mortality; pembrolizumab; survival; urinary bladder neoplasms;
D O I：
10.1111/iju.70040
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Subgroup analysis of real-world efficacy of enfortumab vedotin in patients with metastatic/locally advanced urothelial carcinoma from a European database.
    Darr, Christopher
    Kluemper, Niklas
    Buettner, Thomas
    Holzwarth, Nina
    Biernath, Nadine
    Hoellein, Alexander
    Niegisch, Guenter
    Seidl, Daniel
    Handke, Analena
    Paffenholz, Pia
    Schlack, Katrin
    Cathomas, Richard
    Erne, Eva
    Banek, Severine
    Tauber, Robert
    Casuscelli, Jozefina
    Seitz, Anna Katharina
    Hadaschik, Boris A.
    Gruenwald, Viktor
    Zschaebitz, Stefanie
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] Real-world use, dose intensity, and adherence to enfortumab vedotin in locally advanced or metastatic urothelial cancer
    Mamtani, Ronac
    Tsingas, Konstantinos
    Parikh, Ravi B.
    Elsouda, Dina
    Mucha, Lisa
    Fuldeore, Rupali
    Hubbard, Rebecca A.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2024, 42 (06) : e1 - e4
  • [3] Impact of Skin Adverse Events on Prognosis in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin: A Real-World Multicenter Study
    Ozaki, Kai
    Yamamoto, Hayato
    Sekine, Yuya
    Horiguchi, Hirotaka
    Hosogoe, Shogo
    Mikami, Jotaro
    Fujita, Naoki
    Tokui, Noriko
    Okita, Kazutaka
    Okamoto, Teppei
    Mori, Kanami
    Kobayashi, Mizuki
    Numakura, Kazuyuki
    Yoneyama, Takahiro
    Tabata, Ryuji
    Sato, Satoshi
    Habuchi, Tomonori
    Ohyama, Chikara
    Hatakeyama, Shingo
    INTERNATIONAL JOURNAL OF UROLOGY, 2025,
  • [4] Real-world Effectiveness of Single-Agent Enfortumab Vedotin in Patients With Advanced Urothelial Carcinoma
    Sayegh, Nicolas
    Jo, Yeonjung
    Gebrael, Georges
    Tripathi, Nishita
    Chigarira, Beverly
    Srivastava, Ayana
    Nordblad, Blake
    Dal, Emre
    Chehade, Chadi Hage
    Mahlow, Jon
    Maughan, Benjamin L.
    Gupta, Sumati
    Agarwal, Neeraj
    Swami, Umang
    CLINICAL GENITOURINARY CANCER, 2025, 23 (01)
  • [5] FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma
    Maguire, William F.
    Lee, Daniel
    Weinstock, Chana
    Gao, Xin
    Bulik, Catharine C.
    Agrawal, Sundeep
    Chang, Elaine
    Hamed, Salaheldin S.
    Bloomquist, Erik W.
    Tang, Shenghui
    Pazdur, Richard
    Kluetz, Paul G.
    Amiri-Kordestani, Laleh
    Suzman, Daniel L.
    CLINICAL CANCER RESEARCH, 2024, 30 (10) : 2011 - 2016
  • [6] Safety and efficacy of enfortumab vedotin in patients with metastatic/locally advanced urothelial cancer: Real-world evidence from a European database.
    Zschaebitz, Stefanie
    Kluemper, Niklas
    Holzwarth, Nina
    Biernath, Nadine
    Hoellein, Alexander
    Niegisch, Guenter
    Seidl, Daniel
    Aydogdu, Can
    Handke, Analena
    Paffenholz, Pia
    Schlack, Katrin
    Cathomas, Richard
    Erne, Eva
    Banek, Severine
    Tauber, Robert
    Casuscelli, Jozefina
    Seitz, Anna Katharina
    Gruenwald, Viktor
    Darr, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 553 - 553
  • [7] A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma
    Takahashi, Shunji
    Uemura, Motohide
    Kimura, Tomokazu
    Kawasaki, Yoshihide
    Takamoto, Atsushi
    Yamaguchi, Akito
    Melhem-Bertrandt, Amal
    Gartner, Elaina M.
    Inoue, Takashi
    Akazawa, Rio
    Kadokura, Takeshi
    Tanikawa, Toshiki
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (04) : 1056 - 1066
  • [8] A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma
    Shunji Takahashi
    Motohide Uemura
    Tomokazu Kimura
    Yoshihide Kawasaki
    Atsushi Takamoto
    Akito Yamaguchi
    Amal Melhem-Bertrandt
    Elaina M. Gartner
    Takashi Inoue
    Rio Akazawa
    Takeshi Kadokura
    Toshiki Tanikawa
    Investigational New Drugs, 2020, 38 : 1056 - 1066
  • [9] Treatment Patterns, Healthcare Resource Utilization, and Costs Among Patients Diagnosed With Locally Advanced/Metastatic Urothelial Carcinoma Prior to Receiving Enfortumab Vedotin: A Real-World Evidence Study
    Morgans, Alicia K.
    Mucha, Lisa
    Quicquaro, Christina
    Shih, Vanessa
    Xie, Bin
    Young, Christopher
    Yang, Hongbo
    Liu, Qing
    Greatsinger, Alexandra
    Lax, Angela
    INTERNATIONAL JOURNAL OF UROLOGY, 2025,
  • [10] Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
    O'Donnell, Peter H.
    Milowsky, Matthew I.
    Petrylak, Daniel P.
    Hoimes, Christopher J.
    Flaig, Thomas W.
    Mar, Nataliya
    Moon, Helen H.
    Friedlander, Terence W.
    McKay, Rana R.
    Bilen, Mehmet A.
    Srinivas, Sandy
    Burgess, Earle F.
    Ramamurthy, Chethan
    George, Saby
    Geynisman, Daniel M.
    Bracarda, Sergio
    Borchiellini, Delphine
    Geoffrois, Lionnel
    Rey, Jose Pablo Maroto
    Ferrario, Christiano
    Carret, Anne-Sophie
    Yu, Yao
    Guseva, Maria
    Moreno, Blanca Homet
    Rosenberg, Jonathan E.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (25) : 4107 - +
12345